- Home
- CRI vs IMNM Comparison
CRI vs IMNM Comparison
Compare CRI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRI
- IMNM
- Stock Information
- Founded
- CRI 1865
- IMNM 2006
- Country
- CRI United States
- IMNM United States
- Employees
- CRI N/A
- IMNM N/A
- Industry
- CRI Apparel
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- CRI Consumer Discretionary
- IMNM Health Care
- Exchange
- CRI Nasdaq
- IMNM Nasdaq
- Market Cap
- CRI 1.0B
- IMNM 945.8M
- IPO Year
- CRI 2003
- IMNM 2020
- Fundamental
- Price
- CRI $28.75
- IMNM $10.52
- Analyst Decision
- CRI Sell
- IMNM Strong Buy
- Analyst Count
- CRI 4
- IMNM 8
- Target Price
- CRI $30.25
- IMNM $24.75
- AVG Volume (30 Days)
- CRI 1.3M
- IMNM 707.2K
- Earning Date
- CRI 10-24-2025
- IMNM 08-06-2025
- Dividend Yield
- CRI 11.13%
- IMNM N/A
- EPS Growth
- CRI N/A
- IMNM N/A
- EPS
- CRI 3.75
- IMNM N/A
- Revenue
- CRI $2,833,315,000.00
- IMNM $12,589,000.00
- Revenue This Year
- CRI $0.81
- IMNM N/A
- Revenue Next Year
- CRI N/A
- IMNM $154.73
- P/E Ratio
- CRI $7.66
- IMNM N/A
- Revenue Growth
- CRI N/A
- IMNM 16.74
- 52 Week Low
- CRI $23.38
- IMNM $5.15
- 52 Week High
- CRI $71.99
- IMNM $16.73
- Technical
- Relative Strength Index (RSI)
- CRI 59.21
- IMNM 55.88
- Support Level
- CRI $27.90
- IMNM $9.13
- Resistance Level
- CRI $29.65
- IMNM $10.28
- Average True Range (ATR)
- CRI 1.04
- IMNM 0.57
- MACD
- CRI 0.46
- IMNM 0.01
- Stochastic Oscillator
- CRI 81.45
- IMNM 87.15
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.